Caroline Young’s SEC Form 4 filing history presents a strikingly one-sided picture: across 149 reported transactions, she has recorded zero open-market sales and zero purchases, with her only cash-equivalent activity being a single $5,040 grant of Cumberland Pharmaceuticals (CPIX) stock on March 18, 2026. That award, coded as a compensation grant rather than a discretionary buy, stands as the sole six-figure event in her record. The remaining 148 filings are all coded "L," a designation indicating small, non-discretionary adjustments—likely dividend reinvestments or minor share corrections—with individual values ranging from roughly $7 to $19.55. These "L" transactions cluster almost daily from late November 2025 through late December 2025, suggesting routine administrative activity rather than a deliberate accumulation or divestment strategy.
The absence of any "P" (open-market purchase) or "S" (open-market sale) codes is the most notable feature of Young’s pattern. Her total buy value of $1,379.40 is entirely attributable to those small "L" entries, not to conviction buying, while her sell value is zero. The $5,040 grant dwarfs all other activity combined, but as a compensatory award it reflects issuer policy, not insider sentiment. The recent trade stream shows no directional shift: the last "L" filing occurred on December 31, 2025, and the only subsequent event was the March 2026 grant. For investors tracking insider conviction, Young’s record offers no signal—no accumulation, no distribution, and no open-market engagement with CPIX shares beyond what the company itself provides.
AI-assisted summary